FDA Will Fast-Track Decision on an Experimental and Controversial Alzheimer’s Drug

On Friday, the pharmaceutical company Biogen announced the Food and Drug Administration accepted its application to conduct a priority review of their experimental Alzheimer’s drug for approval. The speedier-than-usual process sets the stage for the treatment, called aducanumab, to be the first new approved drug for…

Read more...



from Gizmodo https://ift.tt/3fJCbaM

Related Posts


EmoticonEmoticon

:)
:(
=(
^_^
:D
=D
=)D
|o|
@@,
;)
:-bd
:-d
:p
:ng
:lv